Out-Licensing
In association with the Viridian merger, miRagen’s business strategy transitioned to prioritizing VRDN-001 for the development of thyroid eye disease and away from its legacy programs that modulate microRNAs. The presentations and publications listed below provide data on the microRNA programs that are now available for out-licensing, spin out or sale. For further information please contact Outlicensing@viridiantherapeutics.com.
- April 27, 2017 Pharmacodynamic activity of a microRNA-29b mimic (MRG-201) in human skin incisions Society for Investigative Dermatology Annual Meeting
- December 3, 2016 Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA antimiR) of microRNA-155, in Patients with CTCL American Society for Hematology Annual Meeting
- December 6, 2015 Preclinical Results Supporting Therapeutic Development of MRG-106, an Oligonucleotide Inhibitor of miR-155, in CTCL American Society for Hematology Annual Meeting
- September 19, 2014 MicroRNA mimicry blocks pulmonary fibrosis EMBO Molecular Medicine
- February 6, 2013 Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure European Journal of Heart Failure
- February 20, 2012 Circulating microRNAs to identify human heart failure Wiley Online Library
- January 12, 2012 A Cardiac MicroRNA Governs Systemic Energy Homeostasis by Regulation of MED13 Cell
- November 3, 2011 Inhibition of miR-15 Protects Against Cardiac Ischemic Injury Circulation Research
- September 12, 2011 Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure Circulation
- August 1, 2011 Mice lacking microRNA 133a develop dynamin 2–dependent centronuclear myopathy The Journal of Clinical Investigation